Alumis (NASDAQ:ALMS) Stock Price Target Lowered at Wells Fargo & Company

Alumis (NASDAQ:ALMS) had its price objective reduced by Wells Fargo & Company from $25.00 to $18.00 in a research report sent to investors on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Other equities analysts have also issued research reports about the company. Morgan Stanley lowered their target price on Alumis from $39.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Benchmark restated a “buy” rating on shares of Alumis in a research note on Monday, October 5th. Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a research report on Wednesday, September 16th. Finally, Weiss Ratings cut shares of Alumis from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $32.09.

Alumis Price Performance

Alumis stock opened at $5.60 on Friday. Alumis has a twelve month low of $4.60 and a twelve month high of $31.35. The company’s 50-day moving average price is $7.24 and its two-hundred day moving average price is $20.46.

Alumis (NASDAQ:ALMS) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.03. Alumis had a negative net margin of 5,844.54% and a negative return on equity of 86.62%. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.90 million. On average, analysts forecast that Alumis will post -2.95 EPS for the current fiscal year.

Insider Buying and Selling at Alumis

In other news, Director Srinivas Akkaraju sold 96,131 shares of Alumis stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $10.55, for a total value of $1,014,182.05. Following the completion of the sale, the director directly owned 2,025,493 shares in the company, valued at approximately $21,368,951.15. The trade was a 4.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 99,754 shares of company stock valued at $1,037,804 in the last three months. 33.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alumis

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP raised its holdings in Alumis by 188.7% in the 3rd quarter. Marshall Wace LLP now owns 1,062,571 shares of the company’s stock valued at $7,852,000 after acquiring an additional 694,557 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Alumis during the 3rd quarter valued at $706,000. Polymer Capital Management US LLC acquired a new stake in shares of Alumis during the 3rd quarter worth $152,000. First Trust Advisors LP grew its holdings in shares of Alumis by 244.8% during the 3rd quarter. First Trust Advisors LP now owns 324,311 shares of the company’s stock worth $2,397,000 after purchasing an additional 230,265 shares in the last quarter. Finally, Ieq Capital LLC acquired a new stake in shares of Alumis during the 3rd quarter worth $306,000.

Alumis News Roundup

Investors following ALMS have been watching these news items:

• Positive Sentiment: Alumis reported new Phase 3 data showing rapid, durable improvements in plaque psoriasis. The company said envudeucitinib had the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies, reinforcing its potential clinical differentiation. Alumis Q3 2026 financial results and business updates
• Neutral Sentiment: Q3 adjusted performance was slightly better than expected: the loss was $0.73 per share versus the $0.76 consensus, while revenue of $1.91 million was essentially in line with estimates of $1.90 million. The small beat is tempered by continued losses. Alumis earnings results
• Negative Sentiment: Wells Fargo cut its price target to $18 from $25, and HC Wainwright lowered its target to $9 from $15. Both firms kept bullish ratings—Overweight and Buy, respectively—but the reductions may signal more cautious expectations and pressure the stock. Wells Fargo price target report

About Alumis

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.